You are here: Home » Reuters » News
Business Standard

AbbVie says deaths in arthritis trial not linked to drug


REUTERS - AbbVie Inc said on Monday two patients died in a late-stage trial of its rheumatoid arthritis drug but that the deaths were not linked to the drug, which met the study's main goals.The trial was evaluating two doses of the drug upadacitinib - 15 mg and 30 mg - in patients with moderate to severe rheumatoid arthritis, who did not adequately respond to or were intolerant to other anti-rheumatic drugs.Upadacitinib, a once-daily pill, belongs to a class of drugs known as JAK inhibitors, which block inflammation-causing enzymes called Janus kinases and are being used to treat rheumatoid ...

This article is no longer available in our repository.

There could be multiple reasons for this.

First Published: Mon, September 11 2017. 22:19 IST